Company / Cash & Equivalents
Halozyme Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$133.8M
FY2025
5-year range
$115.8M / $234.2M
FY2021-FY2025
Trend
+15.5%
vs FY2024
Sector context
#120 of 207
Health Care
What the data says
At $134M, Halozyme's cash & equivalents ranks #120 of 207 in the Health Care sector. Cash & Equivalents returned to growth in FY2025 after 2 years of decline, reaching $134M.
Based on SEC 10-K filings.
$134M in FY2025 with a 5-year CAGR of -2.0%.
Improved from $118M to $134M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -17.0%
- 5-Year CAGR
- -2.0%
- 10-Year CAGR
- -
Sector benchmark
#120 of 207 in Health CareTop 58% of 207This company $133.8M Sector average $669.5M
▼
-80.0% below sector average
Key checks
Key Insights
- 5-year CAGR of -2.0%, indicating a declining trend.
- In FY2025, cash & equivalents increased 15.5% year-over-year.
- Ranks #120 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2022.
Company context
Key Data Points
- Strong profit margin: 47.9%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 118.2%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $133.8M | +15.5% |
| FY2024 | $115.8M | -2.1% |
| FY2023 | $118.4M | -49.5% |
| FY2022 | $234.2M | +97.3% |
| FY2021 | $118.7M | -19.6% |
| FY2020 | $147.7M | +22.9% |
| FY2019 | $120.2M | +107.4% |
| FY2018 | $57.9M | -65.7% |
| FY2017 | $168.7M | +152.7% |
| FY2016 | $66.8M | +144.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026